Researchers engineered an enzyme capable of removing carboxymethyl-lysine (CML), a prevalent advanced glycation end product, from aged human tissue ex vivo—demonstrating that a form of molecular damage long considered irreversible can be enzymatically reversed. This proof of concept shifts the aging research paradigm from prevention toward active repair of accumulated damage.
Key Points
- CMLase enzyme removes CML from proteins in aged tissue ex vivo
- Directed evolution screened 45,000 structures, evolved 500M+ variants
- Challenges decades-old assumption that AGE damage is permanent
Longevity Analysis
The capacity to reverse specific forms of molecular cross-linking that accumulates in structural proteins—particularly in connective tissue, arterial walls, and the lens—addresses a fundamental constraint on tissue regeneration and functional restoration. CML doesn't merely alter protein chemistry; it activates inflammatory signaling through RAGE receptors, amplifying systemic stress responses. By removing this modification and restoring native protein structure, this approach targets not just a single lesion but a mechanism that compromises multiple downstream functions. This moves beyond slowing damage accumulation to actively repairing tissue that has already been modified, which is clinically significant for conditions where prevention alone cannot restore function to organs that have sustained decades of glycative stress.
Original published by Longevity.Technology, by Eleanor Garth.